That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?